Patents by Inventor Richard M. Weinshilboum

Richard M. Weinshilboum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11122997
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Patent number: 10815534
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 27, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Publication number: 20190194761
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 27, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Patent number: 10220016
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: March 5, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Publication number: 20180098722
    Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke University
    Inventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
  • Publication number: 20180021295
    Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.
    Type: Application
    Filed: February 17, 2016
    Publication date: January 25, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
  • Patent number: 8137977
    Abstract: The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: March 20, 2012
    Assignees: Children's Hospital & Research Center at Oakland, Duke University, Lipomics Technologies, Inc., Mayo Foundation for Medical Education and Research
    Inventors: Rima F. Kaddurah-Daouk, Michelle M. Wiest, Steven M. Watkins, Rebecca Ann Baillie, Madhumita Patnaik, K. Ranga Rama Krishnan, Richard M. Weinshilboum, Ronald M. Krauss
  • Publication number: 20120021920
    Abstract: Materials and methods related to using biomarkers for prediction of response to radiation therapy.
    Type: Application
    Filed: April 1, 2010
    Publication date: January 26, 2012
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Liewei Wang, Richard M. Weinshilboum, Krishna Kalari, Brooke L. Fridley, Yu Xin Qin
  • Patent number: 8048662
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: November 1, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Araba A. Adjei, Eric D. Wieben, Richard M. Weinshilboum, Bianca A. Thomae
  • Publication number: 20110244547
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Application
    Filed: April 5, 2011
    Publication date: October 6, 2011
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Araba A. Adjei, Eric D. Wieben, Richard M. Weinshilboum, Bianca A. Thomae
  • Patent number: 7943355
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Grant
    Filed: August 18, 2010
    Date of Patent: May 17, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Araba A Adjei, Eric D Wieben, Richard M Weinshilboum, Bianca A Thomae
  • Publication number: 20110014678
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Application
    Filed: August 18, 2010
    Publication date: January 20, 2011
    Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Araba A. Adjei, Eric D. Wieben, Richard M. Weinshilboum, Bianca A. Thomae
  • Patent number: 7858306
    Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: December 28, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
  • Publication number: 20100311606
    Abstract: Materials and methods for evaluating cellular response to therapeutic agents.
    Type: Application
    Filed: May 7, 2008
    Publication date: December 9, 2010
    Inventors: Liewei Wang, Richard M. Weinshilboum, Liang Li, Brooke L. Fridley, Krishna Kalari, Daniel Schaid, Matthew M. Ames
  • Patent number: 7820805
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are sulfotransferase allozymes. Methods for determining the sulfonator status of a subject also are described. In addition, methods for predicting the therapeutic efficacy of a compound in a subject are described, as are methods for estimating the dose of a compound to be administered to a subject.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: October 26, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Bianca A. Thomae, Eric D. Wieben, Richard M. Weinshilboum
  • Patent number: 7803921
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to cancer also are described.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: September 28, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Araba A. Adjei, Eric D. Wieben, Richard M. Weinshilboum, Bianca A. Thomae
  • Patent number: 7745187
    Abstract: Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as sulfotransferase allozymes. Methods for determining if a mammal is predisposed to thyroid disease or cancer also are described.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: June 29, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Robert R Freimuth, Eric D Wieben, Richard M Weinshilboum
  • Patent number: 7745185
    Abstract: Isolated sulfotransferase 1A3 nucleic acid molecules and polypeptides that include nucleotide sequence variants and amino acid sequence variants are described. Methods for determining predisposition to particular clinical conditions and methods for determining sulfonator status also are described.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: June 29, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Bianca A. Thomae, Eric D. Wieben, Richard M. Weinshilboum
  • Patent number: 7727737
    Abstract: This document provides methods and materials related to rapid, quantitative determination of TPMT activity in biological samples. Also featured are compositions and kits useful for determination of TPMT activity in biological samples.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: June 1, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: John F. O'Brien, Jean M. Lacey, Mark J. Magera, Richard M. Weinshilboum
  • Patent number: 7674583
    Abstract: Methods are described for determining sulfonator status of a patient and determining dosages of drugs based on copy number of the SULT1A1 gene.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: March 9, 2010
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Richard M. Weinshilboum, Araba A. Adjei, Scott J. Hebbring, Stephen N. Thibodeau